Trials / Recruiting
RecruitingNCT06394492
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
A Randomized, Open-Label, Controlled, Phase III Study of SHR-A1921 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 440 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a randomized, open-label, controlled, phase III study to evaluate the efficacy and safety of SHR-A1921 versus investigator's choice of chemotherapy in patients with platinum-resistant recurrent epithelial ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1921 | SHR-A1921 dose 1 |
| DRUG | Doxorubicin | Doxorubicin dose 2 |
| DRUG | Paclitaxel | Paclitaxel dose 3 |
| DRUG | Topotecan | Topotecan dose 4 |
Timeline
- Start date
- 2024-05-10
- Primary completion
- 2026-05-31
- Completion
- 2026-12-31
- First posted
- 2024-05-01
- Last updated
- 2024-08-09
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06394492. Inclusion in this directory is not an endorsement.